#news #biotech Verona tanks after COPD drug misses phase 2 endpoint

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Verona tanks after COPD drug misses phase 2 endpoint .A phase 2 trial of Verona Pharma’s ensifentrine has missed its primary endpoint. The dual PDE3/PDE4 inhibitor failed to beat placebo on a measure of lung function, wiping more than 30% off Verona’s share price. 

from FierceBiotech: Biotech http://bit.ly/2Rrz0gA